A short-term trial of tacrolimus ointment for atopic dermatitis

Thomas Ruzicka, Thomas Bieber, Erwin Schöpf, Andris Rubins, A. Dobozy, Jan D. Bos, Stefania Jablonska, Imitiaz Ahmed, Kristian Thestrup-Pedersen, Francois Daniel, Aldo Finzi, Sakari Reitamo

Research output: Contribution to journalArticle

475 Citations (Scopus)

Abstract

Background Tacrolimus (FK 506) is an effective immunosuppressant drug for the prevention of rejection after organ transplantation, and preliminary studies suggest that topical application of tacrolimus is effective in the treatment of atopic dermatitis. Methods We conducted a randomized, double- blind, multicenter study that compared 0.03 percent, 0.1 percent, and 0.3 percent tacrolimus ointment with vehicle alone in patients with moderate-to- severe atopic dermatitis. The ointment was applied twice daily to a defined, symptomatic area of 200 to 1000 cm2 of skin for three weeks. The primary end point was the change in the summary score for erythema, edema, and pruritus between the first and last days of treatment. Results After three weeks of treatment, the median percentage decrease in the summary score for dermatitis on the trunk and extremities was 66.7 percent for the 54 patients receiving 0.03 percent tacrolimus, 83.3 percent for the 54 patients receiving 0.1 percent tacrolimus, 75.0 percent for the 51 patients receiving 0.3 percent tacrolimus, and 22.5 percent for the 54 patients receiving vehicle alone (P

Original languageEnglish
Pages (from-to)816-821
Number of pages6
JournalNew England Journal of Medicine
Volume337
Issue number12
DOIs
Publication statusPublished - Sep 18 1997

Fingerprint

Tacrolimus
Atopic Dermatitis
Ointments
Organ Transplantation
Dermatitis
Erythema
Pruritus
Immunosuppressive Agents
Double-Blind Method
Multicenter Studies
Edema
Therapeutics
Extremities
Skin
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Ruzicka, T., Bieber, T., Schöpf, E., Rubins, A., Dobozy, A., Bos, J. D., ... Reitamo, S. (1997). A short-term trial of tacrolimus ointment for atopic dermatitis. New England Journal of Medicine, 337(12), 816-821. https://doi.org/10.1056/NEJM199709183371203

A short-term trial of tacrolimus ointment for atopic dermatitis. / Ruzicka, Thomas; Bieber, Thomas; Schöpf, Erwin; Rubins, Andris; Dobozy, A.; Bos, Jan D.; Jablonska, Stefania; Ahmed, Imitiaz; Thestrup-Pedersen, Kristian; Daniel, Francois; Finzi, Aldo; Reitamo, Sakari.

In: New England Journal of Medicine, Vol. 337, No. 12, 18.09.1997, p. 816-821.

Research output: Contribution to journalArticle

Ruzicka, T, Bieber, T, Schöpf, E, Rubins, A, Dobozy, A, Bos, JD, Jablonska, S, Ahmed, I, Thestrup-Pedersen, K, Daniel, F, Finzi, A & Reitamo, S 1997, 'A short-term trial of tacrolimus ointment for atopic dermatitis', New England Journal of Medicine, vol. 337, no. 12, pp. 816-821. https://doi.org/10.1056/NEJM199709183371203
Ruzicka, Thomas ; Bieber, Thomas ; Schöpf, Erwin ; Rubins, Andris ; Dobozy, A. ; Bos, Jan D. ; Jablonska, Stefania ; Ahmed, Imitiaz ; Thestrup-Pedersen, Kristian ; Daniel, Francois ; Finzi, Aldo ; Reitamo, Sakari. / A short-term trial of tacrolimus ointment for atopic dermatitis. In: New England Journal of Medicine. 1997 ; Vol. 337, No. 12. pp. 816-821.
@article{d1415532c16e49a6907fb3d22eb80515,
title = "A short-term trial of tacrolimus ointment for atopic dermatitis",
abstract = "Background Tacrolimus (FK 506) is an effective immunosuppressant drug for the prevention of rejection after organ transplantation, and preliminary studies suggest that topical application of tacrolimus is effective in the treatment of atopic dermatitis. Methods We conducted a randomized, double- blind, multicenter study that compared 0.03 percent, 0.1 percent, and 0.3 percent tacrolimus ointment with vehicle alone in patients with moderate-to- severe atopic dermatitis. The ointment was applied twice daily to a defined, symptomatic area of 200 to 1000 cm2 of skin for three weeks. The primary end point was the change in the summary score for erythema, edema, and pruritus between the first and last days of treatment. Results After three weeks of treatment, the median percentage decrease in the summary score for dermatitis on the trunk and extremities was 66.7 percent for the 54 patients receiving 0.03 percent tacrolimus, 83.3 percent for the 54 patients receiving 0.1 percent tacrolimus, 75.0 percent for the 51 patients receiving 0.3 percent tacrolimus, and 22.5 percent for the 54 patients receiving vehicle alone (P",
author = "Thomas Ruzicka and Thomas Bieber and Erwin Sch{\"o}pf and Andris Rubins and A. Dobozy and Bos, {Jan D.} and Stefania Jablonska and Imitiaz Ahmed and Kristian Thestrup-Pedersen and Francois Daniel and Aldo Finzi and Sakari Reitamo",
year = "1997",
month = "9",
day = "18",
doi = "10.1056/NEJM199709183371203",
language = "English",
volume = "337",
pages = "816--821",
journal = "New England Journal of Medicine",
issn = "0028-4793",
publisher = "Massachussetts Medical Society",
number = "12",

}

TY - JOUR

T1 - A short-term trial of tacrolimus ointment for atopic dermatitis

AU - Ruzicka, Thomas

AU - Bieber, Thomas

AU - Schöpf, Erwin

AU - Rubins, Andris

AU - Dobozy, A.

AU - Bos, Jan D.

AU - Jablonska, Stefania

AU - Ahmed, Imitiaz

AU - Thestrup-Pedersen, Kristian

AU - Daniel, Francois

AU - Finzi, Aldo

AU - Reitamo, Sakari

PY - 1997/9/18

Y1 - 1997/9/18

N2 - Background Tacrolimus (FK 506) is an effective immunosuppressant drug for the prevention of rejection after organ transplantation, and preliminary studies suggest that topical application of tacrolimus is effective in the treatment of atopic dermatitis. Methods We conducted a randomized, double- blind, multicenter study that compared 0.03 percent, 0.1 percent, and 0.3 percent tacrolimus ointment with vehicle alone in patients with moderate-to- severe atopic dermatitis. The ointment was applied twice daily to a defined, symptomatic area of 200 to 1000 cm2 of skin for three weeks. The primary end point was the change in the summary score for erythema, edema, and pruritus between the first and last days of treatment. Results After three weeks of treatment, the median percentage decrease in the summary score for dermatitis on the trunk and extremities was 66.7 percent for the 54 patients receiving 0.03 percent tacrolimus, 83.3 percent for the 54 patients receiving 0.1 percent tacrolimus, 75.0 percent for the 51 patients receiving 0.3 percent tacrolimus, and 22.5 percent for the 54 patients receiving vehicle alone (P

AB - Background Tacrolimus (FK 506) is an effective immunosuppressant drug for the prevention of rejection after organ transplantation, and preliminary studies suggest that topical application of tacrolimus is effective in the treatment of atopic dermatitis. Methods We conducted a randomized, double- blind, multicenter study that compared 0.03 percent, 0.1 percent, and 0.3 percent tacrolimus ointment with vehicle alone in patients with moderate-to- severe atopic dermatitis. The ointment was applied twice daily to a defined, symptomatic area of 200 to 1000 cm2 of skin for three weeks. The primary end point was the change in the summary score for erythema, edema, and pruritus between the first and last days of treatment. Results After three weeks of treatment, the median percentage decrease in the summary score for dermatitis on the trunk and extremities was 66.7 percent for the 54 patients receiving 0.03 percent tacrolimus, 83.3 percent for the 54 patients receiving 0.1 percent tacrolimus, 75.0 percent for the 51 patients receiving 0.3 percent tacrolimus, and 22.5 percent for the 54 patients receiving vehicle alone (P

UR - http://www.scopus.com/inward/record.url?scp=0242322394&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0242322394&partnerID=8YFLogxK

U2 - 10.1056/NEJM199709183371203

DO - 10.1056/NEJM199709183371203

M3 - Article

C2 - 9295241

AN - SCOPUS:0242322394

VL - 337

SP - 816

EP - 821

JO - New England Journal of Medicine

JF - New England Journal of Medicine

SN - 0028-4793

IS - 12

ER -